Buying AstraZeneca could cause antitrust problems and does not fit GlaxoSmithKline's acquisition strategy, outgoing CEO Jean-Pierre Garnier said at a meeting Wednesday. Such a deal also would weaken research and development productivity because GSK has a stronger pipeline of new drugs than AstraZeneca, Garnier said. A spokesman for AstraZeneca said the company is expected to deliver an average of two treatments per year to market from 2010 onward.

Related Summaries